-DOCSTART- -X- O
Human -X- _ O
parainfluenza -X- _ O
viruses -X- _ O
( -X- _ O
HPIVs -X- _ O
) -X- _ O
are -X- _ O
common -X- _ O
causes -X- _ O
of -X- _ O
severe -X- _ O
pediatric -X- _ O
respiratory -X- _ O
viral -X- _ O
disease. -X- _ O
We -X- _ O
characterized -X- _ O
wild-type -X- _ O
HPIV2 -X- _ O
infection -X- _ O
in -X- _ O
an -X- _ O
in -X- _ O
vitro -X- _ O
model -X- _ O
of -X- _ O
human -X- _ O
airway -X- _ O
epithelium -X- _ O
( -X- _ O
HAE -X- _ O
) -X- _ O
and -X- _ O
found -X- _ O
that -X- _ O
the -X- _ O
virus -X- _ O
replicates -X- _ O
to -X- _ O
high -X- _ O
titer -X- _ O
, -X- _ O
sheds -X- _ O
apically -X- _ O
, -X- _ O
targets -X- _ O
ciliated -X- _ O
cells -X- _ O
, -X- _ O
and -X- _ O
induces -X- _ O
minimal -X- _ O
cytopathology. -X- _ O
Replication -X- _ O
of -X- _ O
an -X- _ O
experimental -X- _ B-Intervention
, -X- _ I-Intervention
live -X- _ I-Intervention
attenuated -X- _ I-Intervention
HPIV2 -X- _ I-Intervention
vaccine -X- _ I-Intervention
strain -X- _ I-Intervention
, -X- _ O
containing -X- _ O
both -X- _ O
temperature -X- _ O
sensitive -X- _ O
( -X- _ O
ts -X- _ O
) -X- _ O
and -X- _ O
non-ts -X- _ O
attenuating -X- _ O
mutations -X- _ O
, -X- _ O
was -X- _ O
restricted -X- _ B-Outcome
> -X- _ I-Outcome
30-fold -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
rHPIV2-WT -X- _ I-Outcome
in -X- _ I-Outcome
HAE -X- _ I-Outcome
at -X- _ I-Outcome
32°C -X- _ I-Outcome
and -X- _ I-Outcome
exhibited -X- _ I-Outcome
little -X- _ I-Outcome
productive -X- _ I-Outcome
replication -X- _ I-Outcome
at -X- _ I-Outcome
37°C. -X- _ I-Outcome
This -X- _ O
restriction -X- _ O
paralleled -X- _ O
attenuation -X- _ O
in -X- _ O
the -X- _ O
upper -X- _ O
and -X- _ O
lower -X- _ O
respiratory -X- _ O
tract -X- _ O
of -X- _ O
African -X- _ O
green -X- _ O
monkeys -X- _ O
, -X- _ O
supporting -X- _ O
the -X- _ O
HAE -X- _ B-Outcome
model -X- _ I-Outcome
as -X- _ I-Outcome
an -X- _ I-Outcome
appropriate -X- _ I-Outcome
and -X- _ I-Outcome
convenient -X- _ I-Outcome
system -X- _ I-Outcome
for -X- _ I-Outcome
characterizing -X- _ I-Outcome
HPIV2 -X- _ I-Outcome
vaccine -X- _ I-Outcome
candidates -X- _ I-Outcome
. -X- _ O

